...
首页> 外文期刊>Journal of Clinical Oncology >Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.
【24h】

Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.

机译:早期不良霍奇金淋巴瘤患者的强化化学疗法和减少剂量的受累野放疗:德国霍奇金研究小组HD11试验的最终分析。

获取原文
获取原文并翻译 | 示例

摘要

PURPOSE: Combined-modality treatment consisting of four to six cycles of chemotherapy followed by involved-field radiotherapy (IFRT) is the standard of care for patients with early unfavorable Hodgkin's lymphoma (HL). It is unclear whether treatment results can be improved with more intensive chemotherapy and which radiation dose needs to be applied. PATIENTS AND METHODS: Patients age 16 to 75 years with newly diagnosed early unfavorable HL were randomly assigned in a 2 x 2 factorial design to one of the following treatment arms: four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) + 30 Gy of IFRT; four cycles of ABVD + 20 Gy of IFRT; four cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP(baseline)) + 30 Gy of IFRT; or four cycles of BEACOPP(baseline) + 20 Gy of IFRT. RESULTS: With a total of 1,395 patients included, the freedom from treatment failure (FFTF) at 5 years was 85.0%, overall survival was 94.5%, and progression-free survival was 86.0%. BEACOPP(baseline) was more effective than ABVD when followed by 20 Gy of IFRT (5-year FFTF difference, 5.7%; 95% CI, 0.1% to 11.3%). However, there was no difference between BEACOPP(baseline) and ABVD when followed by 30 Gy of IFRT (5-year FFTF difference, 1.6%; 95% CI, -3.6% to 6.9%). Similar results were observed for the radiotherapy question; after four cycles of BEACOPP(baseline), 20 Gy was not inferior to 30 Gy (5-year FFTF difference, -0.8%; 95% CI, -5.8% to 4.2%), whereas inferiority of 20 Gy cannot be excluded after four cycles of ABVD (5-year FFTF difference, -4.7%; 95% CI, -10.3% to 0.8%). Treatment-related toxicity occurred more often in the arms with more intensive therapy. CONCLUSION: Moderate dose escalation using BEACOPP(baseline) did not significantly improve outcome in early unfavorable HL. Four cycles of ABVD should be followed by 30 Gy of IFRT.
机译:目的:联合治疗包括四到六个周期的化疗,然后进行累及放疗(IFRT),是早期不良霍奇金淋巴瘤(HL)患者的治疗标准。尚不清楚通过更深入的化疗是否可以改善治疗效果,还需要应用哪种放射剂量。患者和方法:将年龄16至75岁,初次诊断为早期不利HL的患者按2 x 2因子设计随机分配至以下治疗组之一:阿霉素,博来霉素,长春碱和达卡巴嗪(ABVD)的四个周期+ 30 IFRT的Gy;四个周期的ABVD + IFRT 20 Gy;博来霉素,依托泊苷,阿霉素,环磷酰胺,长春新碱,丙卡巴嗪和泼尼松(BEACOPP(基线))+ 30 Gy IFRT的四个周期;或四个BEACOPP(基准)周期+ 20 Gy IFRT。结果:总共纳入1,395例患者,其5年无治疗失败(FFTF)率为85.0%,总生存率为94.5%,无进展生存率为86.0%。当进行20 Gy的IFRT时,BEACOPP(基线)比ABVD更有效(5年FFTF差异,5.7%; 95%CI,0.1%至11.3%)。但是,随后进行30 Gy的IFRT时,BEACOPP(基线)和ABVD之间没有差异(5年FFTF差异为1.6%; 95%CI为-3.6%至6.9%)。对于放疗问题,观察到相似的结果。在四个BEACOPP(基线)周期后,20 Gy不劣于30 Gy(5年FFTF差异,-0.8%; 95%CI,-5.8%至4.2%),而不能排除20 Gy的劣势ABVD周期(5年FFTF差异,-4.7%; 95%CI,-10.3%至0.8%)。与治疗有关的毒性随着强化治疗的发生而更常见于手臂。结论:使用BEACOPP(基线)适度增加剂量并不能显着改善早期不良HL的预后。四个周期的ABVD之后应进行30 Gy的IFRT。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号